ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

This study is currently recruiting patients.

Sponsored by: Walter Reed Army Institute of Research (WRAIR)
Information provided by: Walter Reed Army Institute of Research (WRAIR)

Purpose

This study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. We are looking for volunteers with G6PD deficiency who would be willing to donate blood samples.

Condition Treatment or Intervention
Glucosephosphate Dehydrogenase Deficiency
Favism
  Drug: Primaquine

MedlinePlus related topics:  Anemia;   Food Contamination and Poisoning;   Genetic Disorders;   Metabolic Disorders;   Poisoning

Study Type: Interventional
Study Design: Prevention, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacodynamics Study

Further Study Details: 

Expected Total Enrollment:  14

Study start: December 2003

Eligibility

Ages Eligible for Study:  18 Years   -   60 Years,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria


Location and Contact Information


Maryland
      Walter Reed Army Institute of Research, Silver Spring,  Maryland,  20910,  United States; Recruiting
Felicia L Breedy  866-856-3259    clinical2@na.amedd.army.mil 
Oman Q Salazar  866-856-3259    clinical2@na.amedd.army.mil 
In-Kyu Yoon, M.D.,  Principal Investigator

More Information

Recruitment page for G6PD study

Study ID Numbers:  G6PD; 992
Record last reviewed:  March 2004
Record first received:  January 20, 2004
ClinicalTrials.gov Identifier:  NCT00076323
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-09
line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act